(Reuters) - U.S. biotech group Novavax Inc has joined the race to test coronavirus vaccine candidates on humans and enrolled its first participants on Monday.
Novavax, shares in which surge about 23% to $56.50 in premarket trade, said it expects preliminary readings on safety and on indicators of an immune response from the trial in July.
Already a subscriber? Log in.
Win a prize this Mother's Day by subscribing to our annual plan now! T&C applies.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
